| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 32 | 2024 | 7551 | 1.180 |
Why?
|
| Pulmonary Embolism | 6 | 2015 | 329 | 1.030 |
Why?
|
| Coronary Angiography | 6 | 2014 | 598 | 0.970 |
Why?
|
| Multidetector Computed Tomography | 2 | 2015 | 150 | 0.920 |
Why?
|
| Fluorodeoxyglucose F18 | 13 | 2024 | 1226 | 0.860 |
Why?
|
| Positron Emission Tomography Computed Tomography | 5 | 2024 | 833 | 0.830 |
Why?
|
| Diagnostic Errors | 3 | 2018 | 509 | 0.830 |
Why?
|
| Radiopharmaceuticals | 9 | 2019 | 1301 | 0.770 |
Why?
|
| Calcinosis | 4 | 2014 | 423 | 0.750 |
Why?
|
| Artifacts | 6 | 2015 | 532 | 0.720 |
Why?
|
| Heart | 7 | 2019 | 1223 | 0.720 |
Why?
|
| Positron-Emission Tomography | 10 | 2016 | 2173 | 0.600 |
Why?
|
| Pulmonary Artery | 4 | 2015 | 499 | 0.550 |
Why?
|
| Thoracic Wall | 3 | 2015 | 183 | 0.550 |
Why?
|
| Radiography, Thoracic | 8 | 2017 | 462 | 0.530 |
Why?
|
| Thoracic Neoplasms | 4 | 2007 | 337 | 0.500 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2015 | 592 | 0.500 |
Why?
|
| Myocardium | 3 | 2018 | 1313 | 0.490 |
Why?
|
| Lung Neoplasms | 21 | 2024 | 11538 | 0.490 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2022 | 7702 | 0.480 |
Why?
|
| Heart Neoplasms | 3 | 2015 | 214 | 0.400 |
Why?
|
| Coronary Vessels | 4 | 2011 | 665 | 0.390 |
Why?
|
| Carcinoma, Small Cell | 1 | 2014 | 408 | 0.390 |
Why?
|
| Heart Diseases | 3 | 2019 | 732 | 0.390 |
Why?
|
| X-Ray Intensifying Screens | 1 | 2010 | 33 | 0.390 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2019 | 1648 | 0.370 |
Why?
|
| Coronary Disease | 1 | 2014 | 764 | 0.370 |
Why?
|
| Aortography | 1 | 2010 | 181 | 0.370 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2015 | 882 | 0.360 |
Why?
|
| Contrast Media | 6 | 2010 | 1472 | 0.360 |
Why?
|
| Cardiomyopathies | 2 | 2017 | 610 | 0.360 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2010 | 160 | 0.340 |
Why?
|
| Incidental Findings | 1 | 2010 | 272 | 0.330 |
Why?
|
| Image Enhancement | 2 | 2008 | 561 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 12 | 2020 | 5319 | 0.300 |
Why?
|
| Neoplasms | 10 | 2019 | 15193 | 0.290 |
Why?
|
| Pleural Neoplasms | 2 | 2022 | 470 | 0.280 |
Why?
|
| Mesothelioma | 2 | 2022 | 544 | 0.260 |
Why?
|
| Diagnostic Imaging | 3 | 2015 | 1162 | 0.260 |
Why?
|
| Vascular Neoplasms | 3 | 2015 | 114 | 0.250 |
Why?
|
| Movement | 3 | 2019 | 556 | 0.240 |
Why?
|
| Venous Thrombosis | 2 | 2010 | 384 | 0.230 |
Why?
|
| Electrocoagulation | 1 | 2003 | 65 | 0.230 |
Why?
|
| Humans | 65 | 2024 | 261506 | 0.210 |
Why?
|
| Foreign Bodies | 1 | 2003 | 145 | 0.200 |
Why?
|
| Surgical Flaps | 1 | 2007 | 927 | 0.190 |
Why?
|
| Muscle, Skeletal | 2 | 2007 | 1270 | 0.190 |
Why?
|
| Thrombosis | 1 | 2007 | 781 | 0.180 |
Why?
|
| Respiratory-Gated Imaging Techniques | 1 | 2019 | 51 | 0.180 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 46 | 0.170 |
Why?
|
| Venous Thromboembolism | 2 | 2017 | 335 | 0.170 |
Why?
|
| Coronary Artery Disease | 4 | 2015 | 1011 | 0.170 |
Why?
|
| Respiration | 2 | 2019 | 447 | 0.160 |
Why?
|
| Middle Aged | 31 | 2019 | 86204 | 0.160 |
Why?
|
| Radiographic Image Enhancement | 3 | 2014 | 402 | 0.160 |
Why?
|
| Mediastinal Neoplasms | 1 | 2022 | 423 | 0.160 |
Why?
|
| Tomography, Spiral Computed | 2 | 2010 | 133 | 0.150 |
Why?
|
| Tomography, Emission-Computed | 3 | 2008 | 310 | 0.140 |
Why?
|
| Male | 32 | 2019 | 123000 | 0.130 |
Why?
|
| Fiducial Markers | 1 | 2016 | 96 | 0.130 |
Why?
|
| Sarcoma | 2 | 2006 | 1725 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 2403 | 0.130 |
Why?
|
| Adult | 23 | 2017 | 77950 | 0.130 |
Why?
|
| Vascular Calcification | 1 | 2015 | 50 | 0.120 |
Why?
|
| Sensitivity and Specificity | 8 | 2015 | 4971 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 6009 | 0.120 |
Why?
|
| Pericardium | 3 | 2022 | 157 | 0.120 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2014 | 54 | 0.120 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 304 | 0.110 |
Why?
|
| Cardiology | 1 | 2019 | 530 | 0.110 |
Why?
|
| Female | 32 | 2019 | 141928 | 0.110 |
Why?
|
| Aged | 26 | 2017 | 70117 | 0.110 |
Why?
|
| Osteosarcoma | 2 | 2015 | 929 | 0.110 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2020 | 2104 | 0.100 |
Why?
|
| Prevalence | 3 | 2017 | 3260 | 0.100 |
Why?
|
| Radiography | 5 | 2007 | 1904 | 0.100 |
Why?
|
| Phantoms, Imaging | 2 | 2016 | 1271 | 0.100 |
Why?
|
| Mediastinum | 2 | 2022 | 268 | 0.100 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 3168 | 0.100 |
Why?
|
| Retrospective Studies | 14 | 2017 | 37905 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2009 | 1248 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2017 | 1335 | 0.100 |
Why?
|
| Inhalation | 1 | 2011 | 42 | 0.100 |
Why?
|
| Taxoids | 2 | 2011 | 967 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2019 | 1423 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2008 | 925 | 0.090 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2010 | 71 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 213 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2012 | 221 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 291 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4892 | 0.090 |
Why?
|
| Rabbits | 1 | 2010 | 957 | 0.090 |
Why?
|
| ROC Curve | 1 | 1992 | 1183 | 0.090 |
Why?
|
| Neoplasm Staging | 6 | 2022 | 13658 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 235 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2019 | 6869 | 0.080 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 14289 | 0.080 |
Why?
|
| Bone Neoplasms | 4 | 2015 | 2576 | 0.080 |
Why?
|
| Biomarkers | 1 | 2019 | 5047 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2011 | 15862 | 0.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 355 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2014 | 2803 | 0.080 |
Why?
|
| Aged, 80 and over | 11 | 2017 | 29902 | 0.080 |
Why?
|
| Adipose Tissue, Brown | 2 | 2005 | 112 | 0.080 |
Why?
|
| Sirolimus | 1 | 2011 | 814 | 0.070 |
Why?
|
| Radiology | 1 | 1992 | 434 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2008 | 4744 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2010 | 492 | 0.070 |
Why?
|
| Aorta | 1 | 2010 | 692 | 0.070 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2006 | 88 | 0.070 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 92 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2013 | 1824 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 660 | 0.070 |
Why?
|
| Heart Atria | 1 | 2008 | 352 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2016 | 1577 | 0.070 |
Why?
|
| Pulmonary Fibrosis | 1 | 2006 | 170 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 4988 | 0.060 |
Why?
|
| Prognosis | 3 | 2024 | 21713 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 14889 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 1946 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2019 | 298 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2013 | 1330 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6207 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2011 | 2218 | 0.060 |
Why?
|
| Observer Variation | 3 | 2015 | 671 | 0.060 |
Why?
|
| Electrodes | 1 | 2003 | 116 | 0.060 |
Why?
|
| Heart Ventricles | 1 | 2008 | 846 | 0.060 |
Why?
|
| Research Design | 1 | 2010 | 1544 | 0.060 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 234 | 0.050 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 174 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2020 | 3842 | 0.050 |
Why?
|
| Incidence | 3 | 2020 | 5673 | 0.050 |
Why?
|
| Lung | 2 | 2011 | 3151 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1467 | 0.050 |
Why?
|
| Pleura | 1 | 2022 | 127 | 0.050 |
Why?
|
| Carboplatin | 3 | 2010 | 823 | 0.050 |
Why?
|
| Smoking | 1 | 2010 | 2440 | 0.050 |
Why?
|
| Lung Injury | 1 | 2002 | 131 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 2195 | 0.050 |
Why?
|
| Thymoma | 1 | 2003 | 246 | 0.050 |
Why?
|
| Interdisciplinary Research | 1 | 2019 | 8 | 0.040 |
Why?
|
| Ventricular Dysfunction | 1 | 2019 | 33 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2003 | 400 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 1303 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 216 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2019 | 155 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 160 | 0.040 |
Why?
|
| Radioisotopes | 1 | 2017 | 177 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 15694 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2002 | 902 | 0.040 |
Why?
|
| Adolescent | 4 | 2015 | 31252 | 0.030 |
Why?
|
| Metals | 1 | 2016 | 155 | 0.030 |
Why?
|
| False Positive Reactions | 2 | 2007 | 355 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 3472 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2002 | 1411 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 1866 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2011 | 2231 | 0.030 |
Why?
|
| Neoplasms, Vascular Tissue | 2 | 2003 | 12 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 295 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 12873 | 0.030 |
Why?
|
| Peripheral Nervous System Neoplasms | 2 | 2003 | 72 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 59536 | 0.030 |
Why?
|
| Liver | 1 | 2002 | 2961 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2012 | 191 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 85 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8865 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2017 | 787 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2012 | 195 | 0.020 |
Why?
|
| Heart Rate | 1 | 2014 | 737 | 0.020 |
Why?
|
| Biological Transport | 1 | 2012 | 597 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2010 | 176 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 339 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 226 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2011 | 164 | 0.020 |
Why?
|
| Quality Control | 1 | 2011 | 457 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2019 | 2370 | 0.020 |
Why?
|
| Everolimus | 1 | 2011 | 415 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 7789 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2009 | 227 | 0.020 |
Why?
|
| Risk Factors | 2 | 2019 | 17523 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1529 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 477 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 531 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 4844 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 1290 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 74 | 0.020 |
Why?
|
| Niacinamide | 1 | 2009 | 421 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 361 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2008 | 94 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 3981 | 0.020 |
Why?
|
| Surface Properties | 1 | 2007 | 180 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2012 | 9180 | 0.020 |
Why?
|
| Methotrexate | 1 | 2010 | 999 | 0.020 |
Why?
|
| Neutropenia | 1 | 2011 | 968 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 4367 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 1258 | 0.020 |
Why?
|
| Microcomputers | 1 | 2006 | 36 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 649 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2006 | 88 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 316 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2010 | 938 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2006 | 141 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1014 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2007 | 330 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2005 | 102 | 0.020 |
Why?
|
| Glutamates | 1 | 2005 | 130 | 0.020 |
Why?
|
| Bleomycin | 1 | 2006 | 467 | 0.020 |
Why?
|
| Guanine | 1 | 2005 | 151 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 2139 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6100 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 1987 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2015 | 16273 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 7548 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 21445 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 117 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 185 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 9244 | 0.010 |
Why?
|
| Indoles | 1 | 2009 | 1009 | 0.010 |
Why?
|
| Iatrogenic Disease | 1 | 2005 | 183 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2006 | 829 | 0.010 |
Why?
|
| Lipids | 1 | 2007 | 644 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2004 | 128 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2010 | 3005 | 0.010 |
Why?
|
| Disease Progression | 2 | 2005 | 6682 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 3441 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 726 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 1546 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 1099 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2009 | 1996 | 0.010 |
Why?
|
| Time Factors | 2 | 2007 | 12926 | 0.010 |
Why?
|
| Mass Screening | 1 | 2010 | 1509 | 0.010 |
Why?
|
| Pulmonary Atelectasis | 1 | 2002 | 46 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2007 | 551 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 1323 | 0.010 |
Why?
|
| Diaphragm | 1 | 2002 | 181 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2005 | 1244 | 0.010 |
Why?
|
| Child | 2 | 2015 | 29154 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 1390 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 3251 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5687 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 10001 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 2055 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4320 | 0.010 |
Why?
|
| Biomarkers, Tumor | 2 | 2006 | 10331 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 3890 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 6942 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 5112 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12221 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 7222 | 0.010 |
Why?
|
| United States | 1 | 2010 | 15433 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 1870 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 5437 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 4849 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 10035 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 4654 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 34495 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2003 | 32848 | 0.000 |
Why?
|